Why Option Care Health Stock Zoomed 8% Higher on Tuesday

Option Care Health reported preliminary, unaudited Q4 2025 net sales of $1.46–1.47 billion versus $1.35 billion a year earlier and non-GAAP net income of $73.8–$79.0 million (or $0.46–$0.49 per share) versus prior-year adjusted net profit of $75.5 million. The board authorized an expanded $1.0 billion share repurchase program (up from $500 million previously authorized, with $193 million remaining under the old program), prompting investor optimism and an intraday stock rise of over 8%; the results are preliminary and the company provided no formal commentary. This combination of revenue growth and a materially larger buyback is a positive signal for OPCH equity, though outcomes remain subject to final audited results and additional disclosure.

Analysis

Market structure: OPCH’s preliminary Q4 (net sales $1.46–1.47B vs $1.35B LY, +8%+) and a $1.0B buyback (up from $500M) benefit shareholders, reduce float and support EPS if executed; specialty home-infusion providers and contract specialty pharmacies directly gain pricing/leverage while payers face higher outpatient spend pressure. Revenue growth with essentially flat non‑GAAP net income (~$0.46–0.49 vs prior $75.5M) signals volume-driven top-line but limited margin expansion, so pricing power is moderate and competition on drug procurement and reimbursement will determine share shifts over 6–18 months.

Risk assessment: Tail risks include adverse CMS reimbursement changes, major specialty drug shortages, or a poorly timed buyback (market peak) — each could wipe out 20–40% of equity value in stress scenarios. In the next 1–30 days expect volatility around the official release and buyback execution cadence; over 3–12 months watch realized buybacks (>$400M deployed) and any guidance on margins or contract wins as primary binary catalysts.

Trade implications: Favor a tactical long-biased exposure to OPCH sized 2–4% of equity at current levels with defined-option hedges; use 6–12 week call spreads to capture re-rating if management begins executing >$250M of buybacks in Q1, or sell short-dated puts only if willing to accumulate stock at a 8–12% discount. Broader portfolio: rotate modestly into specialty healthcare services (over general med-tech) and trim rate-sensitive cyclical stocks given potential equity-supportive buybacks and defensive cash flows.

Contrarian angles: The market may be underpricing margin risk — revenue growth without net income expansion implies mix shift or cost creep; upside is contingent on buyback efficiency and sustainable margin recovery, not just one-quarter revenue. If buybacks are executed early and opportunistically (>$500M within 6 months), upside could be >25%; if reimbursement headwinds intensify, downside could exceed 30%, so size positions accordingly and avoid levered exposure.

Key Decisions for Investors

• Establish a 2–4% long position in OPCH (Option Care Health) within 5 trading days, funded on strength but staggered in tranches (50% now, 25% on a ≤5% pullback, 25% on confirmation of >$250M buyback execution); target 15–25% upside, stop-loss 12%.
• Buy a 6–12 week call spread on OPCH (bull call spread) sized to equal 1–2% portfolio risk to capture re-rating if quarterly release confirms margin improvement or buyback execution; cap premium with defined width to limit downside.
• Sell 4–8 week cash-secured put(s) at ~8–12% below current market price to accumulate OPCH at a discount; only if willing to own at that level and with aggregate notional <=2% portfolio.
• Pair trade: long OPCH (2%) vs short 1% position in a diversified healthcare ETF (e.g., XLV or IYH) for 3–6 months to isolate specialty services outperformance driven by buybacks and revenue growth.
• Do not increase leverage or size >6% total net exposure until OPCH publishes audited Q4 results and provides buyback cadence; reassess within 30 days of management commentary or a CMS reimbursement announcement.